Abstract
The circulating proteome offers insights into the biological pathways that underlie disease. Here, we test relationships between 1,468 Olink protein levels and the incidence of 23 age-related diseases and mortality, ascertained over 16 years of electronic health linkage in the UK Biobank (N=49,234). We report 3,123 associations between 1,052 protein levels and incident diseases (PBonferroni < 5.4×10−6). Forty-four proteins are indicators of eight or more morbidities. Next, protein-based scores (ProteinScores) are developed using penalised Cox regression. When applied to test sets, eight ProteinScores improve Area Under the Curve (AUC) estimates for the 10-year onset of incident outcomes (PBonferroni < 0.0025) beyond age, sex and additional health and lifestyle covariates. The type 2 diabetes ProteinScore outperforms HbA1c (P = 5.7×10−12) – a clinical marker used to monitor and diagnose type 2 diabetes. A maximal type 2 diabetes model including the ProteinScore, HbA1c and a polygenic risk score has AUC = 0.90 and Precision-Recall AUC = 0.76. These data characterise early proteomic contributions to major age-related disease.
Competing Interest Statement
B.B.S., R.A., J.G., T.L., K.F., and H.R., are employed by Biogen. C.N.F., Z.K., D.A.G., and T.M., are employed by Optima partners. D.A.G., R.F.H., and R.E.M., have received consultancy fees from Optima Partners. R.E.M. is an advisor to the Epigenetic Clock Development Foundation. R.F.H., has received consultant fees from Illumina. All other authors declare no competing interests.
Funding Statement
This research was funded in whole, or in part, by the Wellcome Trust [108890/Z/15/Z]. For the purpose of open access, the author has applied a CC BY public copyright licence to any Author Accepted Manuscript version arising from this submission. We thank the participants, contributors, and researchers of UK Biobank for making data available for this study with special thanks to Lauren Carson, John Busby, Naomi Allen and Rory Collins for making the study possible. We are grateful to the research & development leadership teams at the thirteen participating UKB-PPP member companies (Alnylam Pharmaceuticals, Amgen, AstraZeneca, Biogen, Bristol Myers Squibb, Calico, Genentech, Glaxo Smith Klein, Janssen Pharmaceuticals, Novo Nordisk, Pfizer, Regeneron, and Takeda) for funding the study. We thank the Legal and Business Development teams at each company for overseeing the contracting of this complex, precompetitive collaboration with particular thanks to Erica Olson of Amgen, Andrew Walsh of GSK, and Fiona Middleton of AstraZeneca. The Biogen team is especially thankful to Helen McLaughlin for her project management support. Finally, we thank the team at Olink Proteomics (Philippa Pettingell, Klev Diamanti, Cindy Lawley, Linda Jung, Sara Ghalib, Ida Grundberg and Jon Heimer) for their consistent logistic support throughout the project with special thanks to Evan Mills for co championing the project and leading internal activities at Olink. R.E.M. is supported by Alzheimers Society major project grant AS-PG-19b-010. R.F.H is supported by a MRC IEU Fellowship. D.A.G. is supported by the Wellcome Trust Translational Neuroscience programme [108890/Z/15/Z].
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
All participants provided informed consent. This research has been conducted using the UK Biobank Resource under approved application numbers 65851, 20361, 26041, 44257, 53639, 69804.
I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable.
Yes
Data Availability
Datasets generated in this study are made available in Supplementary Tables. These data will also be deposited in an open-access repository upon publication. Proteomics data is available in UK Biobank under return dataset [return dataset ID and URL will be provided upon publication, depending on time of official publication].
https://gitfront.io/r/user-2029007/EKPBzX5Fh2KV/UKB-project/
